

Traitement de mélanomes par flavonoïdes


Basé sur le travail de Raimundo Gonçalves de Oliveira-Júnior et al. : « Polymethoxyflavones from *Gardenia oudiepe* (Rubiaceae) induce cytoskeleton disruption-mediated apoptosis and sensitize BRAF-mutated melanoma cells to chemotherapy », *Chemico-Biological Interactions*, Volume 325, 2020, <https://doi.org/10.1016/j.cbi.2020.109109>.

Une série de 10 flavonoïdes sont obtenus à partir de la Rubiacée *Gardenia oudiepe*, une plante endémique de Nouvelle Calédonie. Ces molécules ont une activité cytotoxique que l'on cherche à exploiter pour traiter les mélanomes. On teste ici leur efficacité respective.

Un commentaire organisé des figures et tableaux est attendu. Des questions supplémentaires sont spécifiées sous les documents

N'hésitez pas à demander de l'aide si des problèmes de vocabulaire se posent.

Table 1. Chemical structures and antiproliferative activity of compounds 1-10.

Substitution pattern	Compound (PMF)	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	Antiproliferative activity (%)
	1	OMe	OH	OMe	OH	H	OH	H	18.55 ± 5.16
	2	OMe	OH	OMe	OH	H	OMe	H	66.53 ± 5.71
	3	OMe	OH	OMe	OH	OMe	OMe	OH	42.86 ± 8.27
	4	OMe	OH	OMe	OH	OMe	OMe	OMe	5.68 ± 5.00
	5	OMe	OH	H	OH	H	OH	H	22.29 ± 6.69
	6	OMe	OH	H	OH	OMe	OMe	OH	20.80 ± 6.50
	7	OMe	OH	H	OMe	OMe	OMe	OH	29.48 ± 4.95
	8	OMe	OH	H	OMe	H	OMe	H	29.79 ± 9.77
	9	OAc	OH	H	OAc	H	OAc	H	7.04 ± 7.39
	10	OAc	OAc	H	OAc	H	OAc	H	10.13 ± 5.27

Mean ± SEM of at least 3 determinations. PMF: polymethoxyflavone. All compounds were tested at 10 μM.




Figure 1. Effect of PMFs 2 and 3 on A2058 melanoma cells viability. Cells were cultured in the presence of increasing concentrations of molecules (1 – 20 μM) for 72h and then cell viability was determined by the MTT assay. Results are expressed as mean ± SEM of at least three independent measurements.

Wikipedia : The MTT assay is a colorimetric assay for assessing cell metabolic activity.





Figure 2. Pro-apoptotic effect of PMFs **2** (4 µM, ~IC₅₀) and **3** (8 µM, ~IC₅₀) on A2058 melanoma cells. (A) Photomicrographs were obtained after 72h of treatment using Annexin-V/6-CFDA double staining + DAPI for DNA staining of permeable cells. (B) Caspase-3 activity was determined by colorimetric assay. Staurosporine (2 µM, 4h) was used as positive control. Data are expressed as mean ± SEM, **p* < 0.05 (vs. control group), according to ANOVA one-way followed by Tukey's post-test (n=3).

DAPI colore l'ADN des cellules perméables, l'Annexin-V se lie à la phosphatidylsérine présente à dans l'hémimembrane externe des cellules et le 6-CFDA induit une fluorescence des cellules vivantes. Comment ces colorations permettent-elles la mise en évidence d'une apoptose induite ?




Figure 4. Effect of compounds **2** (2 μM, $\sim 1/2IC_{50}$) and **3** (4 μM, $\sim 1/2IC_{50}$) on cell mobility after 24h (A) and 48h (B) of treatment. Photomicrographs illustrate cell migration into the zone free of cells according to the treatment (C). Data are expressed as mean \pm SEM, * $p < 0.05$ (ANOVA one-way followed by Tukey's post-test), from at least three independent measurements.

Proposez des hypothèses sur le mécanisme d'inhibition de la motilité.

Pourquoi la motilité des cellules est-elle un paramètre important dans le traitement du cancer ?




Fig. 11. Chemosensitizing effect of PMFs 2 and 3 on A2058 cells. (A): antiproliferative effect of vemurafenib (Vemu, 1–100 μM) alone or in the presence of compounds 2 and 3 ($\sim 1/2\text{IC}_{50}$). (B): antiproliferative effect of dacarbazine (Daca, 1–100 μM) alone or in the presence of compounds 2 and 3 ($\sim 1/2\text{IC}_{50}$). (C): combination index for the association of dacarbazine with PMF 2. (D) photomicrographs show reduction of cell density promoted by combined therapy, compared to monotherapies and control group. Results are expressed as mean \pm SEM, $^*p < 0.05$ according to unpaired Student's *t*-test, from at least three independent measurements.

Étude de l'effet combiné des molécules d'intérêts avec d'autres médicaments connus.

Proposez une analyse critique du document. (On ne s'intéressera pas à la figure C).